Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiaxiang Ding

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Antiviral Therapy|September 10, 2025
Pharmacokinetic and mass balance characterization of [<sup>14</sup>C] RAY1216, a SARS-CoV-2 M<sup>pro</sup> inhibitor, in healthy Chinese male subjectsWang Hu, Jiaxiang Ding, Yunqiu Xie, et al.
Frontiers in Pharmacology|January 21, 2022
TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver DiseaseHuan Zhou, Xingyu Zhu, Yan Yao, et al.
BMC Pharmacology & Toxicology|February 22, 2023
Oseltamivir phosphate for suspension is bioequivalent to TAMIFLU in healthy volunteers: a randomized, open-label clinical studyYing Wang, Bangzhong Tang, Jing Xie, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 7, 2023
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumorHongtao Li, Rongfang Shan, Jiaxiang Ding, et al.
Journal of Diabetes Research|December 29, 2023
A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter StudyYuetong Zhao, Lin Liu, Li Zuo, et al.
Cancer Chemotherapy and Pharmacology|December 26, 2022
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [<sup>14</sup>C] SHC014748M in healthy Chinese subjects following oral administrationFei Guo, Bingyan Liu, Xiaoli Li, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Antiviral Therapy|September 10, 2025
Pharmacokinetic and mass balance characterization of [<sup>14</sup>C] RAY1216, a SARS-CoV-2 M<sup>pro</sup> inhibitor, in healthy Chinese male subjectsWang Hu, Jiaxiang Ding, Yunqiu Xie, et al.
Frontiers in Pharmacology|January 21, 2022
TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver DiseaseHuan Zhou, Xingyu Zhu, Yan Yao, et al.
BMC Pharmacology & Toxicology|February 22, 2023
Oseltamivir phosphate for suspension is bioequivalent to TAMIFLU in healthy volunteers: a randomized, open-label clinical studyYing Wang, Bangzhong Tang, Jing Xie, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 7, 2023
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumorHongtao Li, Rongfang Shan, Jiaxiang Ding, et al.
Journal of Diabetes Research|December 29, 2023
A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter StudyYuetong Zhao, Lin Liu, Li Zuo, et al.
Cancer Chemotherapy and Pharmacology|December 26, 2022
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [<sup>14</sup>C] SHC014748M in healthy Chinese subjects following oral administrationFei Guo, Bingyan Liu, Xiaoli Li, et al.
Pageof 4